Last reviewed · How we verify
SCB-2019
At a glance
| Generic name | SCB-2019 |
|---|---|
| Sponsor | Clover Biopharmaceuticals AUS Pty |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults (PHASE3)
- Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults (PHASE3)
- Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (PHASE3)
- Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (PHASE1)
- A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (PHASE2, PHASE3)
- Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes. (PHASE3)
- Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age (PHASE2, PHASE3)
- Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCB-2019 CI brief — competitive landscape report
- SCB-2019 updates RSS · CI watch RSS
- Clover Biopharmaceuticals AUS Pty portfolio CI